Profound Medical is committed to change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.
Profound Medical is a Canadian medical device company located in Mississauga, ON. The company is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.
TULSA-PRO® is CE marked and Profound Medical is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions.
The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO® in the United States.
Profound Medical is also commercializing Sonalleve MR-HIFU an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The Company is also in the early stages of exploring additional potential treatment markets for Sonalleve MR-HIFU, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.
Profound Medical is a Canadian medical device company located in Mississauga, ON. The company is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.
TULSA-PRO® is CE marked and Profound Medical is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions.
The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO® in the United States.
Profound Medical is also commercializing Sonalleve MR-HIFU an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The Company is also in the early stages of exploring additional potential treatment markets for Sonalleve MR-HIFU, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.
Location: Canada, Ontario, Mississauga
Employees: 51-200
Founded date: 2008
Investors 4
| Date | Name | Website |
| - | MaRS Inves... | marsiaf.co... |
| - | CIBC Innov... | innovation... |
| - | Genesys Ca... | genesyscap... |
| - | BDC | bdc.ca/ |
Mentions in press and media 8
| Date | Title | Description |
| 10.12.2024 | Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares | TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares ... |
| 06.12.2024 | Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares | BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” ... |
| 06.12.2024 | Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares | BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” ... |
| 07.03.2024 | Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results | - |
| 04.03.2024 | Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference | TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablat... |
| 30.05.2023 | Profound Medical Announces Upcoming Investor Events | /EIN News/ -- TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies f... |
| 27.04.2021 | Busch Center Performs World’s First TULSA-PRO Procedure on Patient with Pacemaker | The Busch Center at www.buschcenter.com. “We are proud to be the first facility in the world to perform the TULSA-PRO procedure on a patient with a pacemaker. This provides the opportunity for more men to receive this effective procedure th... |
| 06.11.2019 | BDC spinout Amplitude Ventures closes half of newly-launched $200 million health fund | Amplitude Ventures, a Montréal-headquartered investment firm focused on health and the life sciences sectors has announced the launch of a targeted $200 million CAD venture fund. The firm is a spin-out of the Business Development Bank of Ca... |